Compare Repligen Corporation Common Stock (RGEN) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Texas Instruments Incorporated — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Texas Instruments Incorporated trades at $279.75 (market cap $262.88B). The key difference: Texas Instruments Incorporated is far larger — about 23.6× Repligen Corporation Common Stock's market cap, and Texas Instruments Incorporated pays a 2.11% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Texas Instruments Incorporated for 77 Days on average.
| RGEN | TXN | |
|---|---|---|
Market Cap | $11.14B | $262.88B |
Volume | 1,259,263 | 5,600,379 |
Sector | Health | Technology |
52-Week High | $194.57 | $332.35 |
52-Week Low | $102.87 | $153.33 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $11.02B | $269.93B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Texas Instruments (TXN) trades at $281.74, down 0.7% on the day, with a neutral technical signal. The stock shows strong profitability with a 31.11% net income margin and 34.97% ROE, though valuation ratios like a P/E of 43.75 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and data center sales growth is a key driver, with news highlighting a 55% year-to-date gain as of September 2026.
The outlook is positive with a consensus price target of $325, implying 15% upside, supported by AI and industrial demand. Risks include high debt-to-asset ratio of 40.61% and semiconductor cycle volatility. Analyst sentiment is mixed but leans bullish with 48% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
